2.3 Federal Food, Drug, and Cosmetic Act (FDCA)

The FDCA: A Different Federal Statute, A Different Federal Agency

While the CSA and DEA govern which substances are controlled and how they move through the distribution chain, a separate federal statute governs whether a drug may be marketed at all, how it must be labeled, and what makes it "prescription" versus "over-the-counter": the Federal Food, Drug, and Cosmetic Act (FDCA), originally enacted in 1938 and codified at 21 USC §§ 301 et seq., administered by the Food and Drug Administration (FDA) — not DEA. A drug can be entirely non-controlled under the CSA (gabapentin, most antibiotics, most cardiovascular medications) and still be subject to extensive FDCA requirements around approval, labeling, and manufacturing quality. The MPJE tests both frameworks because a pharmacist's daily practice runs through both at once — the CSA governs a fentanyl patch's ordering and refill rules, while the FDCA governs whether that same patch is legally marketed, properly labeled, and dispensed only pursuant to a valid order.

Prescription vs. OTC: The Durham-Humphrey Amendment

The original 1938 Act required "adequate directions for use" on drug labeling but did not clearly separate prescription drugs from those safe for consumers to select and use themselves. The Durham-Humphrey Amendment of 1951 closed that gap by amending FDCA § 503(b) (21 USC § 353(b)) to create the modern legend-drug framework:

A pharmacist who dispenses a legend drug without a valid prescription — or who allows refills beyond what the prescriber authorized — creates a violation under the FDCA's misbranding provisions and under state practice law at the same time.

Misbranding and Adulteration: The Two Core Enforcement Concepts

The FDCA gives FDA two overlapping but analytically distinct enforcement hooks, and MPJE questions frequently test whether a candidate can tell them apart:

• Misbranding (FDCA § 502; 21 USC § 352) is a labeling and information defect. A drug is misbranded if its labeling is false or misleading, fails to bear required warnings or adequate directions for use, omits the established name or quantity of ingredients, or — critically for pharmacy practice — is a legend drug dispensed without a valid prescription. Dispensing without a valid Rx effectively strips the drug of the lawful "prescription" status its labeling assumes, rendering it misbranded in the hands of the dispenser. A correctly manufactured drug with an inaccurate or incomplete label is misbranded, not adulterated.
• Adulteration (FDCA § 501; 21 USC § 351) is a physical or manufacturing quality defect. A drug is adulterated if it contains a filthy, putrid, or decomposed substance; was prepared, packed, or held under unsanitary conditions; was manufactured in a facility not meeting current Good Manufacturing Practice (cGMP) standards; or fails to meet the strength, quality, or purity standards of an official compendium (the United States Pharmacopeia, or USP) that it claims to meet. A drug compounded outside the applicable USP sterile or nonsterile standards is adulterated, independent of how it is labeled.

A single product can be both misbranded and adulterated at once — for example, a compounded sterile product made under unsanitary conditions and shipped without adequate directions for use — but the two concepts test different failures: one tests what the label says, the other tests what the product physically is.

REMS: Risk Evaluation and Mitigation Strategies

For certain drugs where FDA determines that ordinary labeling is not enough to ensure that benefits outweigh risks, FDA may require a Risk Evaluation and Mitigation Strategy (REMS) under FDCA § 505-1 as a condition of approval or as a post-marketing requirement. A REMS can layer up to three components, escalating in intensity:

1. A Medication Guide or patient package insert, given to the patient at the point of dispensing.
2. A communication plan directed at health care providers (for example, "Dear Healthcare Provider" letters describing a new risk).
3. Elements to Assure Safe Use (ETASU) — the most restrictive tier, which can require prescriber certification or training, pharmacy certification, patient enrollment in a registry, mandatory monitoring such as laboratory testing, or dispensing only through a restricted distribution network.

Two REMS programs are commonly tested because they illustrate the ETASU tier concretely: isotretinoin's iPLEDGE program, which requires prescriber and pharmacy certification, patient enrollment, and a negative pregnancy test before each dispensing because of severe teratogenicity risk; and clozapine's REMS, which requires prescriber, pharmacy, and patient enrollment plus absolute neutrophil count (ANC) monitoring because of the risk of severe, potentially fatal neutropenia. A pharmacist who dispenses a REMS-restricted drug without verifying that the ETASU requirements have been satisfied — for example, dispensing clozapine without a current ANC result on file — is out of compliance with the drug's condition of approval, independent of whether the prescription itself otherwise looks facially valid.

How the Approval Pathway Relates to Pharmacy Practice

While the full mechanics of FDA drug approval sit outside the MPJE's day-to-day dispensing focus, one distinction recurs on jurisprudence exams: a New Drug Application (NDA) under § 505(b)(1) requires full safety and efficacy data for a new drug, while an Abbreviated New Drug Application (ANDA) under § 505(j) lets a generic manufacturer rely on the innovator's established safety and efficacy findings by instead demonstrating bioequivalence — that the generic product's rate and extent of absorption fall within FDA-defined confidence intervals of the brand-name reference product. This is why generic drugs can reach the market faster and at lower cost than new molecular entities, and why an AB-rated generic is presumed therapeutically equivalent for pharmacist substitution purposes.

Common MPJE Traps in This Section

1. Confusing misbranding with adulteration. Misbranding is a labeling/information problem; adulteration is a physical/manufacturing quality problem. A product can be either, both, or neither.
2. Assuming any legend-drug dispensing error is automatically "adulteration." Dispensing a legend drug without a valid prescription is a misbranding violation under § 502, not adulteration.
3. Treating REMS as identical to standard labeling. ETASU-tier REMS impose enforceable dispensing conditions that go beyond routine package labeling; verifying REMS compliance is the dispensing pharmacist's own professional obligation, not only the manufacturer's or FDA's.
4. Mixing up NDA and ANDA. Only the ANDA pathway relies on bioequivalence in place of independent clinical efficacy trials.
5. Believing the FDCA and CSA are the same statute. They are separate federal laws, administered by separate agencies (FDA versus DEA), addressing separate questions — whether a drug is lawfully marketed and labeled, versus whether a drug is controlled and how it must move through the distribution chain.